Table 2.
Patients (%) in olaparib arm: any-grade AEs reported in >15% or grade ≥3 AEs reported in >5% of patients overall
| Adverse event | Study 4250
|
Study 1949
|
SOLO-253
|
|||
|---|---|---|---|---|---|---|
| Any grade | G ≥3 | Any grade | G ≥3 | Any grade | G ≥3 | |
| Fatigue | 60.1 | 6.2 | 48.5 | 6.6 | 66 | – |
| Nausea | 61.7 | 0.5 | 68.4 | – | 76 | – |
| Vomiting | 38.9 | 2.6 | 31.6 | – | 38 | – |
| Anemia | 32.1 | 18.7 | 19.8 | 5.1 | 43 | 19 |
| Diarrhea | 29.0 | 1.6 | 22.8 | – | 33 | – |
| Abdominal pain | 30.1 | 7.3 | 17.6 | – | 25 | – |
| Decreased appetite | 18.7 | 0.5 | 18.4 | – | 22 | – |
| Dyspepsia | 19.7 | 0 | 16.2 | – | – | – |
| Headache | 16.6 | 0 | 18.4 | – | 26 | – |
| Dysgeusia | 20.2 | 0 | – | – | 27 | – |
| Constipation | – | – | – | – | 21 | – |
| Cough | – | – | – | – | 17 | – |
| Arthralgia | – | – | – | – | 15 | – |
| Neutropenia | – | – | – | – | 19 | 5 |
Abbreviation: AEs, adverse events.